公开(公告)号：US20250059182A1

公开(公告)日：2025-02-20

申请号：US18571051

申请日：2022-06-21

Applicant: Mirati Therapeutics, Inc.

Inventor： John Michael Ketcham ,  Christopher Ronald Smith ,  Matthew Arnold Marx ,  Xiaolun Wang ,  Aaron Craig Burns ,  Svitlana Kulyk ,  Anthony Ivetac ,  John David Lawson

IPC: C07D471/04 ,  A61K31/502 ,  A61K31/5025 ,  A61K31/5377 ,  A61K31/5386 ,  C07D237/34 ,  C07D403/04 ,  C07D405/12 ,  C07D413/04 ,  C07D487/04 ,  C07D519/00

Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

公开(公告)号：US20240368153A1

公开(公告)日：2024-11-07

申请号：US18572110

申请日：2022-06-29

Applicant: Mirati Therapeutics, Inc.

Inventor： Christopher Ronald Smith ,  Svitlana Kulyk ,  Matthew Arnold Marx ,  John David Lawson ,  Anthony Ivetac ,  Xiaolun Wang ,  Aaron Craig Burns

IPC: C07D471/04 ,  A61K31/4365 ,  A61K31/437 ,  A61K31/4375 ,  A61K31/498 ,  A61K31/506 ,  A61K31/551 ,  C07D471/14 ,  C07D495/04

Abstract: The present invention relates to compounds that inhibit Protein Arginine N-Methyl Transferase 5 (PRMT5) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

公开(公告)号：US20240309020A1

公开(公告)日：2024-09-19

申请号：US18644056

申请日：2024-04-23

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： Xiaolun Wang ,  Aaron Craig Burns ,  James Gail Christensen ,  John Michael Ketcham ,  John David Lawson ,  Matthew Arnold Marx ,  Christopher Ronald Smith ,  Shelley Allen ,  James F. Blake ,  Mark Joseph Chicarelli ,  Joshua Ryan Dahlke ,  Donghua Dai ,  Jay Bradford Fell ,  John Peter Fischer ,  Macedonio J. Mejia ,  Brad Newhouse ,  Phong Nguyen ,  Jacob Matthew O'Leary ,  Spencer Pajk ,  Martha E. Rodriguez ,  Pavel Savechenkov ,  Tony P. Tang ,  Guy P.A. Vigers ,  Qian Zhao ,  Dean Russell Kahn ,  John Gaudino ,  Michael Christopher Hilton

IPC: C07D519/00

CPC classification number: C07D519/00

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US11964989B2

公开(公告)日：2024-04-23

申请号：US17869575

申请日：2022-07-20

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： Xiaolun Wang ,  Aaron Craig Burns ,  James Gail Christensen ,  John Michael Ketcham ,  John David Lawson ,  Matthew Arnold Marx ,  Christopher Ronald Smith ,  Shelley Allen ,  James F. Blake ,  Mark Joseph Chicarelli ,  Joshua Ryan Dahlke ,  Donghua Dai ,  Jay Bradford Fell ,  John Peter Fischer ,  Macedonio J. Mejia ,  Brad Newhouse ,  Phong Nguyen ,  Jacob Matthew O'Leary ,  Spencer Pajk ,  Martha E. Rodriguez ,  Pavel Savechenkov ,  Tony P. Tang ,  Guy P.A. Vigers ,  Qian Zhao ,  Dean Russell Kahn ,  John Gaudino ,  Michael Christopher Hilton

IPC: C07D519/00

CPC classification number: C07D519/00

Abstract: Compounds that inhibit KRas G12D. In particular, compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor, and in particular, methods of treating cancer. The compounds have a general structure represented by Formula (I):




or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230101312A1

公开(公告)日：2023-03-30

申请号：US17801733

申请日：2021-02-23

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  John Michael Ketcham ,  Christopher Ronald Smith ,  John David Lawson ,  Aaron Craig Burns ,  Xiaolun Wang

IPC: C07D471/04 ,  C07D217/22 ,  C07D401/04 ,  C07D409/12 ,  C07D413/14

Abstract: The present invention relates to compounds that inhibit Son of sevenless homolog 1 (SOS1) activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

公开(公告)号：US11999753B2

公开(公告)日：2024-06-04

申请号：US17553224

申请日：2021-12-16

Applicant: Mirati Therapeutics, Inc.

Inventor： Xiaolun Wang ,  Anthony Ivetac ,  Svitlana Kulyk ,  John David Lawson ,  Matthew Arnold Marx ,  Christopher Ronald Smith

IPC: C07D471/04 ,  A61K31/519 ,  A61P35/00 ,  C07D519/00

CPC classification number: C07D519/00 ,  A61P35/00 ,  C07D471/04

Abstract: The present invention relates to compounds that inhibit at least one of KRas wild type, KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20230357277A1

公开(公告)日：2023-11-09

申请号：US18027300

申请日：2021-09-21

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： Xiaolun Wang ,  Matthew Arnold Marx ,  Shelley Allen ,  Mark Joseph Chicarelli ,  Joshua Ryan Dahlke ,  Donghua Dai ,  Jay Bradford Fell ,  John Peter Fischer ,  Michael Christopher Hilton ,  Dean Russell Kahn ,  Macedonio Junior Mejia ,  Phong Nguyen ,  Spencer Pajk ,  Martha E. Rodriguez ,  Pavel Yu Savechenkov ,  Tony Pisal Tang

IPC: C07D519/00 ,  A61P35/00

CPC classification number: C07D519/00 ,  A61P35/00

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20230339976A1

公开(公告)日：2023-10-26

申请号：US18020013

申请日：2021-08-03

Applicant: Mirati Therapeutics, Inc. ,  Array BioPharma Inc.

Inventor： Xiaolun Wang ,  Matthew Arnold Marx ,  John David Lawson ,  Shelley Allen ,  Patrick Michael Barbour ,  James Francis Blake ,  Joshua Ryan Dahlke ,  Donghua Dai ,  Jay Bradford Fell ,  John Peter Fischer ,  Sherif Hosam Hassanien ,  Michael Christopher Hilton ,  Macedonio Junior Mejia ,  Jacob Matthew O’Leary ,  Tony Pisal Tang

IPC: C07D471/04 ,  C07D519/00

CPC classification number: C07D519/00 ,  C07D471/04

Abstract: The present invention relates to compounds that inhibit KRas G12D. In particular, the present invention relates to compounds that inhibit the activity of KRas G12D, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20230072276A1

公开(公告)日：2023-03-09

申请号：US17300930

申请日：2021-12-15

Applicant: Mirati Therapeutics, Inc.

Inventor： Xiaolun Wang ,  Svitlana Kulyk ,  John David Lawson ,  Matthew Arnold Marx ,  Christopher Ronald Smith

IPC: C07D519/00 ,  C07D471/04

Abstract: The present invention relates to compounds that inhibit at least one of KRas G12A, KRas G12C, KRas G12D, KRas G12R, KRas G12S, KRas G12V, KRas G13D and KRas Q61H, pharmaceutical compositions comprising the compounds and methods of use therefor.

公开(公告)号：US20230137886A1

公开(公告)日：2023-05-04

申请号：US18071384

申请日：2022-11-29

Applicant: Mirati Therapeutics, Inc.

Inventor： Matthew Arnold Marx ,  John Michael Ketcham ,  Christopher Ronald Smith ,  John David Lawson ,  Aaron Craig Burns ,  Xiaolun Wang ,  Svitlana Kulyk ,  Anthony Ivetac

IPC: C07D487/04 ,  C07D409/12 ,  C07D409/14 ,  C07D413/04 ,  C07D403/04 ,  C07D487/08 ,  C07D471/04 ,  C07D471/10 ,  C07D487/10 ,  C07D498/10 ,  C07D471/08 ,  C07D237/34

Abstract: The present invention relates to methods of treating cancer using compounds that inhibit Son of sevenless homolog 1 (SOS1) activity and pharmaceutical compositions containing such compounds.